Business
Candel develops biological multimodal immunotherapies for cancer, led by aglatimagene and linoserpaturev.
Candel had no FY2025 revenue, narrowed its net loss to $38.2M, but cash burn worsened and equity declined.
The read at a glance✓ Audited against SEC data
- Business mix — Cancer viral immunotherapyNote
- Revenue — No revenue rowNote
- Net income — Loss $38.2M, improvedOK
- FCF — -$38.9M, worse 43.9%Watch
- Insiders — $3.0M purchase / 1 saleOK
- Accounting — Altman distressWatch
- Balance — Equity $51.9M, -21.7%Watch
Leadership changes
From Candel Therapeutics, Inc.'s own filings, the day they're filed.
- Charles Schoch · Chief Financial Officer · appointmenteff. 2025-06-20
- Maha Radhakrishnan · directors · appointmenteff. 2025-06-04
- Charles Schoch · Chief Financial Officer · appointmenteff. 2024-01-12
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-05-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Candel Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.